Studies have shown that Around 15 - 25% of women with early breast cancer hae a type called HER2-receptor positive disease. It has been shown that the HER2 receptor is oer-expressed in prostate cancer cells. HER2-positive cancer has strong infiltration and shorter disease-free survival.
HER2, belongs to the Epidermal Growth Factor receptor family, is one of The most v?lnerable oncogene in human tumor. it can control cancer cell growth, invasion and metastasis of cancer cells, The HER2-positive tumors is a high risk of cancer. Herceptin has received FDA approval. Herceptin has demonstrated unprecedented efficacy in treating both early and advanced (metastatic) HER2 positive breast cancer. Herceptin is suitable for treatment of HER2 Overexpressing cancer. The drug is effective only for the HER2 gene amplification and protein overexpression in patients. so that an accurate assessment of HER2 gene And protein levels Is essential. Herceptin is a humanised antibody designed to target and block the function of HER2, a protein produced by a specific gene with cancer-causing potential. Herceptin has been shown to reduce the risk of disease recurrence in women with HER2-positive early cancer. Herceptin is currently being evaluated for treatment of HER2-positive sto mach cancer through an extensive international clinical trial programme. The mode of action of Herceptin is unique in that it activates the body's immune system and suppresses HER2 to target and destroy the tumour. It is also approved for use in combination with an aromatase inhibitor for the treatment of post-menopausal patients with HER2 and hormone receptor co-positive metastatic cancer.
Herceptin received approval for use in the European Union for advanced (metastatic) HER2-positive breast cancer in 2000, and for early HER2-positive breast cancer in 2006. Herceptin received approval in the European Union in 2000 for use in patients with metastatic (advanced) breast cancer, whose tumours overexpress the HER2 protein. The patients need to do HER2 testing, diagnosis of cancer was negative or positive. In cancer patient, her2 masculine breast cancer patient's worsened speed often is higher than the negative patient. If you do not do that and blind to take surgery. missed the best time for treatment, some diseases are accumulated by the medicine surface alleviation function cover Cheng Dabing.
is a new star of Cancer Rehabilitation Website it will be to provide the latest information about Traditional Chinese Medicine(TCM) Breast cancer treatment lung cancer mesothelioma Cancer Rehabilitation info. HER2-positive breast cancer survival time was 1 to 3 years, and HER2-negative patients survived at least 4 to 6 years. if check the status of HER2 in time and use the right treatment, Chances of survival of HER2-positive patients with breast cancer will be close to normal. If determined that her2 is a masculine gender, should in view of her2 gene marching song proper bead Shan Kangba to the treatment, reduce the recrudescence risk promptly.
iAutoblog the premier autoblogger software
